Gland Pharma wins U.S. FDA approval for Sugammadex Injection; shares rise over 4%
AI Market Summary
Gland Pharma received U.S. FDA approval for its Sugammadex Injection ANDA, a bioequivalent generic to Merck's Bridion, and launched immediately via a marketing partner. With IQVIA citing roughly $1.6B in U.S. sales over the past 12 months, the approval strengthens the company's U.S. injectable portfolio and revenue opportunity. The market reaction is primarily idiosyncratic to the issuer rather than broad risk assets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.32%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
India’s Gland Pharma has received U.S. FDA approval for its abbreviated new drug application for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials. The product is a bioequivalent generic version of Merck Sharp & Dohme’s Bridion Injection and is used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. The company said it launched the product on the day of approval through its marketing partner. U.S. sales for the product were around $1.6 billion in the 12 months ended April 2026, according to IQVIA data cited by Gland Pharma.
